Trial Match

SOPHiA DDM™ Trial Match

Maximize enrollment through precise patient matching in biomarker-driven clinical trials

Real-World Data
Consultative Approach
Real-Time Notifications
Global Reach

Learn more about our approach to patient-trial matching

First Name(Required)

Last Name(Required)

Institution(Required)

Role(Required)

Email(Required)

Phone(Required)

Country(Required)

Comments

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Pardot Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

CAPTCHA

Name

This field is for validation purposes and should be left unchanged.

Harness the global and decentralized SOPHiA DDM™ Platform

750+ Healthcare
Institutions¹

70+
Countries

1.3 Million
Genomic
Profiles²

Diversified
Footprint

1. Represents active customers who have generated revenue through the SOPHiA DDM™ platform usage or Alamut™ Visual Plus licenses as of September 30, 2022. 2. Since December 31, 2021

Drive Clinical Development At Key Stages



Clinical Trial Design

Identify sites that best meet your biomarker requirements right from the start



Clinical Trial Rescue

Discover new sites or leverage Real-Time notifications to identify additional potentially eligible profiles for your ongoing trials

CASE STUDY | Trial rescue via profile identification

trial-match_0000s_0000_Screenshot-2023-07-24-at-10.48.50

Trial Overview

Stage: Phase III
Enrollment goal: 216 participants
Disease: NSCLC
Biomarker: EGFR ex19del and EGFR
L858R

trial-match_0000s_0001_Screenshot-2023-07-24-at-10.48.52

Roadblock

No visibility on the genetic testing practices for this biomarker

trial-match_0000s_0002_Screenshot-2023-07-24-at-10.48.54

Strategy

An alert was activated for profiles analyzed through the SOPHiA
DDM™ Platform

trial-match_0000s_0003_Screenshot-2023-07-24-at-10.48.56

Results

Within a span of 4 months, 40+ new potentially eligible profiles were identified

trial-match_0000s_0004_Screenshot-2023-07-24-at-10.49.00

Conclusion

The sponsor and site were promptly notified to facilitate coordinated patient recruitment efforts

GET IN TOUCH

SMARTER PATIENT RECRUITMENT

Spend less time building your healthcare network. Spend more time bringing your trials to the right patient groups.



Download Your Mock Report

READ OUR PUBLICATIONS



Investigating real-world molecular testing within both clinical trial selected sites and surrounding sites to identify eligible study patients – a model for streamlined precision medicine clinical trial operations in oncology
Mol Cancer Ther 2019;18(Suppl 12):A085. https://doi.org/10.1158/1535-7163.TARG-19-A085



The landscape of MET alterations in European cancer patients
Ann of Oncol 2021; 32(Suppl 5):S400. https://doi.org/10.1016/j.annonc.2021.08.381

GET IN TOUCH

SOPHiA DDM™ Trial Match

Learn more about our approach to patient-trial matching